ISRCTN77332530
Active, not recruiting
未知
A feasibility randomised controlled trial assessing the use of platelet transfusions versus modified dose anticoagulation in patients with thrombocytopaenia and cancer-associated thrombosis receiving anticoagulation (START UK)
niversity College London0 sites20 target enrollmentJuly 8, 2024
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Patients with cancer-associated thrombosis and thrombocytopaenia
- Sponsor
- niversity College London
- Enrollment
- 20
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Adult participants (age \=18 years) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed)
- •2\. Imaging confirmed pulmonary embolism, deep vein thrombosis (proximal or distal, including central venous catheter\-related DVT), or unusual site VTE (either symptomatic or incidentally diagnosed) within the last 14 days for which anticoagulation is planned (including VTE in the deep vein system that progressed from a prior superficial vein thrombosis for which anticoagulation is to be started)
- •3\. Platelet count \<50 x 10e9/L from cancer therapy or malignancy itself
- •4\. Able to provide written informed consent
Exclusion Criteria
- •1\. Receipt of anticoagulant for index VTE with platelet count \<50 x10 9/L for \>72 hours
- •2\. Superficial vein thrombosis only
- •3\. Tumour thrombus
- •4\. Life expectancy \<1 month (as judged by the treating physicians)
- •5\. Creatinine clearance \< 30 ml/min
- •6\. Contraindication to LMWH such as a history of heparin induced thrombocytopaenia
- •7\. Thrombocytopaenia from other causes, such as thrombotic microangiopathy, immune thrombocytopaenia, disseminated intravascular coagulation
- •8\. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies
- •9\. Refusal of blood products
- •10\. Anticoagulation at any dose is deemed unsafe (i.e. recent, active bleeding or inherited bleeding disorders)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
PROTECTIVE-D: imPROving the effecTivenEss of vaccinaTion wIth positive mood and Vitamin DVitamin D supplementation and/or positive mood intervention after vaccinationInfections and InfestationsISRCTN12950625niversity of Nottingham28
Completed
Not Applicable
The CHICO (Children with Cough) trialISRCTN23547970niversity of Bristol (UK)500
Completed
Not Applicable
A randomized controlled trial to assess feasibility and practicability of oatmeal intervention in metabolic impaired patients with diabetes mellitus type 2: a pilot study in the outpatient sectorDiabetes mellitus type 2E11Type 2 diabetes mellitusDRKS00033580niversitätsklinikum Jena17
Completed
Not Applicable
A randomised controlled trial of the feasibility and effectiveness of Internet-based interventions for depression in a telephone counselling settingISRCTN93903959The Australian National University (Australia)400
Completed
Not Applicable
IFE Study: Liver transplant recipient Initiative: Feasibility study to Enhance cardio-metabolic healthACTRN12617001260314Princess Alexandra Hospital35